Characterization of the Fungal Origins in the Autoimmune Polyendocrinopathy of Type 1 Compared With the Autoimmune Polyendocrinopathies of Type 2 (APECED2)

University Hospital, Lille

Status: Enrolling

Conditions: Polyendocrinopathies, Autoimmune

Study type: Observational

Funder types: Other

Identifiers

NCT03800056

2017_36

2017-A03135-48 (Other Identifier)

Details and patient eligibility

About

Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is an autosomal recessive disease caused by mutations in the autoimmune regulator (AIRE) gene, characterized by the clinical triad of chronic mucocutaneous candidiasis (CMC), hypoparathyroidism, and adrenal insufficiency. CMC can be complicated by systemic candidiasis or oral squamous cell carcinomas (SCCs) and may lead to death. The role of chronic Candida infection in the etiopathogenesis of oral SCC is unclear. Long term use of fluconazole lead to emergence of C. albicans strains with azoles decreased susceptibility. CMC is associated with an impaired Th17 cell response, however, it remains unclear whether decreased serum IL-17 and IL-22 levels are related to a defect in cytokine production or to neutralizing autoantibodies resulting from mutations in the AIRE gene

Enrollment: 30 estimated patients

Sex: All

Ages: Under 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. For both of groups, inclusion criteria are :

   • children aged 0 to 17 years old with the consent of both parents, and men and women between the ages of 18 and 85.
   • a reasonable delay of 2 weeks after the resolution of an intercurrent infectious episode is to be observed.
   • assent of the patient after information adapted to his age and his degree of understanding.
   • informed, express and written consent of the patient or of each of the holders of parental authority.

2. Inclusion criteria specific to group 1: Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.

3. Inclusion criteria specific to group 2 : Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.

Exclusion criteria

• impossibility to receive informed information for adults, or impossibility to receive enlightened information for the holders of parental authority if minor subject
• inability to participate in the entire study, refusal to sign the consent.
• people in an emergency situation.
• persons deprived of their liberty.
• pregnant or lactating woman (pregnant women will be offered to participate in the study after delivery).

Trial design

30 participants in 2 patient groups

Group 1 APS 1

Description:

Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment.

Group 2 APS2

Description:

Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.